LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

Home・Lista de Ações・Kura Oncology Inc

Kura Oncology Inc

Abrir

SetorSaúde

8.9 -7.58

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.75

Máximo

9.93

Indicadores-chave
By Trading Economics
Rendimento	-6.9M -81M
Vendas	-3.4M 17M
Margem de lucro	-467.23
Funcionários	260
EBITDA	-12M -86M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+195.79% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	89M 844M
Abertura anterior	16.48
Fecho anterior	8.9

Sentimento de Notícias

By Acuity

77%

23%

320 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

5.575 / 6.6 Suporte e Resistência

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mai. de 2026, 22:50 UTC

Ganhos

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 de mai. de 2026, 22:49 UTC

Ganhos

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 de mai. de 2026, 22:32 UTC

Ganhos

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Ganhos

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 de mai. de 2026, 22:26 UTC

Ganhos

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure Interim Dividend A$0.50/Security

12 de mai. de 2026, 22:24 UTC

Ganhos

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 de mai. de 2026, 22:19 UTC

Ganhos

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 de mai. de 2026, 22:13 UTC

Ganhos

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 de mai. de 2026, 22:11 UTC

Ganhos

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 de mai. de 2026, 22:11 UTC

Ganhos

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 de mai. de 2026, 22:10 UTC

Ganhos

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 de mai. de 2026, 22:08 UTC

Ganhos

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 de mai. de 2026, 22:07 UTC

Ganhos

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 de mai. de 2026, 22:05 UTC

Ganhos

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

195.79% parte superior

Previsão para 12 meses

Média 28.13 USD 195.79%

Máximo 40 USD

Mínimo 15 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para Kura Oncology Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

5.575 / 6.6Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

320 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.